Short answer
Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for quarter ended September 30, 2026.
Krystal Biotech, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Detailed financial results and management commentary in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- 3Q revenue $127.3M, up 30% YoY, with 94% gross margin, reinforcing VYJUVEK’s commercial momentum
- 3Q net income $63.1M, down from $79.4M as income tax expense rose to $17.1M
- Cash and investments $1.2B, supporting pipeline expansion and global commercialization without apparent near-term funding pressure
- Board authorized $400M share repurchase program over the next two years, potentially supporting per-share value while reducing financial flexibility
- KB113 showed regression in over 80% of assessed BCC lesions in a three-patient Gorlin syndrome study, an early but clinically limited proof-of-concept signal
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Krystal Biotech, Inc. 8-K filings
Get the next KRYS 8-K as it lands
Follow KRYS for push alerts, or ask the research agent what this filing means.